Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or standard-of-care cetuximab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI). No participants will be given placebo. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better,

Trial Details

NCT ID

NCT07702032

Phase

PHASE3

Sponsor

Genmab

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Petosemtamab
Cetuximab
FOLFIRI
mFOLFOX6

Locations (sample)

Hot Springs, Arkansas, United States|34.5037,-93.05518
Los Angeles, California, United States|34.05223,-118.24368
Savannah, Georgia, United States|32.08354,-81.09983
Warner Robins, Georgia, United States|32.61574,-83.62664
Indianapolis, Indiana, United States|39.76838,-86.15804

Key Eligibility Criteria

Histologically or cytologically confirmed left-sided colorectal adenocarcinoma that is unresectable or metastatic.
Must have documented KRAS and NRAS wild type (wt) colorectal cancer (CRC), as determined by medical record of results from local testing or as asse…
Has not received any prior systemic therapy for unresectable or metastatic CRC.
Must be eligible for treatment with mFOLFOX6 (if assigned to receive mFOLFOX6) or FOLFIRI (if assigned to receive FOLFIRI) according to local regul…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →